BIT Capital GmbH lifted its stake in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 182.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 67,840 shares of the company's stock after purchasing an additional 43,840 shares during the period. BIT Capital GmbH owned about 0.14% of Immunocore worth $2,001,000 at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. Wellington Management Group LLP raised its holdings in Immunocore by 10.5% in the third quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company's stock valued at $219,430,000 after acquiring an additional 668,382 shares in the last quarter. FMR LLC increased its holdings in shares of Immunocore by 0.5% in the 3rd quarter. FMR LLC now owns 4,836,040 shares of the company's stock valued at $150,546,000 after acquiring an additional 23,436 shares during the last quarter. Primecap Management Co. CA raised its position in shares of Immunocore by 8.0% during the 4th quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company's stock worth $78,722,000 after acquiring an additional 196,530 shares in the last quarter. Bellevue Group AG lifted its stake in Immunocore by 4.4% during the third quarter. Bellevue Group AG now owns 1,205,464 shares of the company's stock worth $37,526,000 after purchasing an additional 50,810 shares during the last quarter. Finally, Two Sigma Advisers LP increased its stake in Immunocore by 65.6% in the third quarter. Two Sigma Advisers LP now owns 757,700 shares of the company's stock valued at $23,587,000 after purchasing an additional 300,200 shares during the last quarter. Institutional investors and hedge funds own 84.50% of the company's stock.
Immunocore Price Performance
IMCR stock traded down $0.43 on Monday, reaching $29.16. The company had a trading volume of 118,480 shares, compared to its average volume of 441,273. The company's fifty day moving average is $30.03 and its 200 day moving average is $30.94. The company has a market cap of $1.46 billion, a P/E ratio of -30.69 and a beta of 0.79. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. Immunocore Holdings plc has a 1 year low of $27.19 and a 1 year high of $66.00.
Insider Activity
In other news, Director Bros. Advisors Lp Baker acquired 807,338 shares of the business's stock in a transaction dated Monday, March 17th. The stock was acquired at an average price of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the transaction, the director now directly owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This represents a 60.40 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 9.10% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on IMCR. Needham & Company LLC reiterated a "buy" rating and set a $71.00 target price on shares of Immunocore in a research report on Wednesday, March 12th. HC Wainwright reissued a "buy" rating and issued a $100.00 price objective on shares of Immunocore in a report on Wednesday, March 12th. Finally, Morgan Stanley reiterated an "equal weight" rating and set a $35.00 price target on shares of Immunocore in a research note on Friday, March 7th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $65.64.
View Our Latest Report on Immunocore
Immunocore Profile
(
Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Further Reading
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
